

*Grifols increases its payout to almost
40% of net profit*

Grifols holds its Ordinary General Meeting of Shareholders

- **Allocation of 34.8 million euros to dividends approved, recorded in the results for the financial year 2007**

Barcelona, 13 June 2008: Grifols, the holding company which specializes in the health and pharmaceuticals sector and is one of the world's leading producers of plasma derivatives, has held its Ordinary General Meeting of Shareholders at the first time of calling, with the representation of 574 shareholders, holders of 144.9 million of shares, representing 69.1% of the company's share equity.

The high level of votes delegated to the Board of Directors, accounting for 59.3% of the share capital, is evidence of the shareholders' endorsement of the group's management and the business plan they have followed, and of the strategy for the future which is being implemented. This has seen the share price rise by over 331% since flotation on 17 May 2006, and by 24.7% during the current year (percentages calculated up to 12 June 2008).

The President of the company, Victor Grifols, highlighted Grifols' positive performance during 2007. *"Excellent results which have scarcely been affected by the turbulence of the financial markets. This year all of our divisions have achieved growth, and total sales exceeded 703 million euros, with net profit of 87.8 million euros"*.

He also stressed that *"the continuous process of establishing goals and planning in order to achieve them are two of the engines which have guided this company over recent decades,"* and drew attention to *"the ambitious 400 million euro investment plan approved in 2007 which will drive Grifols' growth over the next 10 years, making us a leader in the production of plasma derivatives, not just in terms of sales turnover, but also because of the levels of excellence, safety and assurance we offer."*

Grifols increases shareholder rewards through dividends

In addition to the inspection and approval of the individual and consolidated accounts of the company for 2007, and the corresponding management reports, the meeting also approved payment of an ordinary dividend of 0.165 euros gross per share recorded in the 2007 results. This sum will be paid by BBVA from 23 July 2008, through Iberclear and participating bodies.

In total, Grifols will allocate 34.8 million euros to dividends, as a result of which its *payout* represents around 40% of net profit, compared to the 28.2% approved by the AGM for the financial year 2006. The result is that Grifols has increased shareholder rewards through dividends, a policy which it expects to maintain in the future.

The decision reflects a set of results which, together with the subscribed syndicated funding for a value of 350 million euros, will allow the group both to finance its investment plan for the period 2008-2012 and to respond to any investment opportunities which might arise as a result of the group's international expansion plans and in accordance with its existing vertically integrated business model.

Finally, at the proposal of the Board of Directors, the General Meeting of Shareholders approved the re-election for the statutory period of five years of Christian M. c. Purslow as independent director.

Grifols announces creation of two new social foundations

In his final contribution, the Chairman, Victor Grifols, told the General Meeting of the establishment of two new foundations with social and humanitarian aims.

With the aim of allocating 0.7% of its profits to social and humanitarian projects, the company has established a foundation through which it will organise projects and channel funds to contribute to:

1. improving health resources in those regions of the world where these are in short supply
2. promoting training and information in health issues in these areas
3. providing aid to areas affected by natural or human disasters.

In order to achieve these objectives, the foundation will have access to the human, material, technical and financial resources of the group's companies and will promote the involvement of all the stakeholders in the Grifols group, as the chairman, Victor Grifols, explained:

"Grifols Engineering will lead this project, because of its extensive know-how in water treatment equipment, the construction of clean rooms and many other types of hospital installation. At the same time, our team of young, enterprising employees, motivated by a strong sense of solidarity, will provide added value to the project. We also want to encourage the involvement of all our stakeholders, including shareholders, investors, suppliers and customers, in realising this project."

Victor Grifols also announced the recent creation of the José Antonio Grifols Lucas Foundation in the United States, with the mission of working in the areas of education and health to promote the welfare of almost a million people who live in the communities which are home to those who donate plasma at Grifols' collection centres.

The foundation pays homage to Dr. J.A. Grifols, inventor of plasmapheresis, and

recognises the importance of our donors and the vital contribution they make to saving lives by donating plasma and the products which are obtained from it.

In addition to these two new social foundations, Grifols already works with the Víctor Grifols i Lucas Foundation, set up in 1998 as an independent body, and created to provide a platform to promote the study and development of ethics and bioethics in the field of human health in general and in the pharmaceutical industry in particular.

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Continuous Market and forms part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments and those which will be carried out in 2008-2012, representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply with 77 plasmapheresis centres in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.